Metabolism & weight
Cagrilintide
Combined with semaglutide as CagriSema
An investigational, once-weekly version of amylin, a fullness hormone released with insulin.
What it is
A lab-made, long-acting analogue of amylin, a hormone the pancreas releases alongside insulin after meals. It is being developed by Novo Nordisk, mainly in combination with semaglutide (CagriSema).
How it's thought to work
It activates amylin and calcitonin receptors in the brain, which increases feelings of fullness and slows stomach emptying. This is a different pathway from GLP-1, so the two can be combined.
What the evidence shows
In a phase 2 trial, cagrilintide alone produced up to about 10.8% average weight loss at 26 weeks, versus 3.0% with placebo. In the phase 3 REDEFINE 1 trial, the CagriSema combination produced about 20.4% average weight loss at 68 weeks, versus 3.0% with placebo.
Regulatory status
Investigational. CagriSema was submitted to the US FDA in December 2025 but was not approved as of November 2026. Cagrilintide alone is not approved.
Safety notes
Digestive side effects such as nausea, constipation and diarrhea were the most common in trials.
Key sources
- Lau DCW, et al. Once-weekly cagrilintide for weight management. Lancet. 2021. Find on PubMed
- Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025. Find on PubMed
Educational summary only, not medical advice. Gtides does not sell or link to sellers of Cagrilintide or any other product. Products sold as “research peptides” are not approved medicines, and their contents, purity and sterility are not verified.